MedTrace Logo

Do Knee Injections Offer Benefit With Knee Arthritis Pain

NCT04017949 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 75

Last updated 2020-04-06

No results posted yet for this study

Summary

Corticosteroid and viscosupplementation injections have been used for years to treat osteoarthritic pain in knees. Recent studies have varied in reporting the effectiveness with these injections. None have been found to analyze pain scores between the groups though.

This study aims to evaluate the effectiveness of corticosteroid injection (a single injection of 1 cc of 40 mg kenalog: 4 cc 0.5% Naropin) and viscosupplementation injection (Euflexxa and Synvisc, both are 2 cc of the medication given in 3 injections over a 3 week period). This will be analyzed with a modified visual analog scale over a period of time. An initial VAS will be collected prior to the first injection in the clinic. With the viscosupplementation injections, a VAS will be collected prior to injections 2 and 3 as well. These VAS are logged in the patient's chart. For both types of injections, the participant will be called and a VAS will be recorded 6 weeks post injection and 3 month post injection. These VAS will NOT be logged in the participant's chart. All VAS will be collected/recorded by the principal investigator. Statistical analysis will be conducted with a paired t-test (p\<0.05 with a confidence interval at 95%) from the pre-injection VAS and VAS subsequently.

Conditions

Interventions

DRUG

Corticosteroid injection

1 cc (40 mg) of a corticosteroid (kenalog) is given

Sponsors & Collaborators

  • University of Pittsburgh

    lead OTHER

Principal Investigators

  • William J Vascik, MPAS, PA-C · Senior Physician Assistant

Eligibility

Min Age
40 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-08-21
Primary Completion
2020-03-01
Completion
2020-03-01
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04017949 on ClinicalTrials.gov